These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 12907552)

  • 21. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
    Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
    Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
    Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
    Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer.
    Kosacka M; Jankowska R
    Pol Arch Med Wewn; 2009; 119(1-2):33-7. PubMed ID: 19341176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
    Mady EA
    Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.
    Boher JM; Pujol JL; Grenier J; Daurès JP
    Br J Cancer; 1999 Mar; 79(9-10):1419-27. PubMed ID: 10188885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer.
    Reinmuth N; Brandt B; Semik M; Kunze WP; Achatzy R; Scheld HH; Broermann P; Berdel WE; Macha HN; Thomas M
    Lung Cancer; 2002 Jun; 36(3):265-70. PubMed ID: 12009236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients.
    Bréchot JM; Chevret S; Nataf J; Le Gall C; Frétault J; Rochemaure J; Chastang C
    Eur J Cancer; 1997 Mar; 33(3):385-91. PubMed ID: 9155521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients.
    Pujol JL; Molinier O; Ebert W; Daurès JP; Barlesi F; Buccheri G; Paesmans M; Quoix E; Moro-Sibilot D; Szturmowicz M; Bréchot JM; Muley T; Grenier J
    Br J Cancer; 2004 Jun; 90(11):2097-105. PubMed ID: 15150567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.
    Ray P; Quantin X; Grenìer J; Pujol JL
    Cancer Detect Prev; 1998; 22(4):293-304. PubMed ID: 9674872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor markers kinetic in malignant lung neoplasms.
    Cristofori R; Aimo G; Mengozzi G; Oliaro A; Revello F; Rapellino M
    J Cardiovasc Surg (Torino); 1999 Apr; 40(2):299-305. PubMed ID: 10350122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer.
    Bates J; Rutherford R; Divilly M; Finn J; Grimes H; O'Muircheartaigh I; Gilmartin JJ
    Eur Respir J; 1997 Nov; 10(11):2535-8. PubMed ID: 9426091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
    Ebert W; Muley T
    Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma.
    Quillien V; Raoul JL; Laurent JF; Meunier B; Le Prise E
    Oncol Rep; 1998; 5(6):1561-5. PubMed ID: 9769406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases.
    Kashiwabara K; Nakamura H; Kiguchi T; Matsuoka T
    Clin Chim Acta; 1998 May; 273(1):35-42. PubMed ID: 9620468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.
    Cho A; Hur J; Hong YJ; Lee HJ; Kim YJ; Hong SR; Suh YJ; Im DJ; Kim YJ; Lee JS; Shim HS; Choi BW
    Tumour Biol; 2016 Mar; 37(3):3205-13. PubMed ID: 26432331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.
    Stieber P; Dienemann H; Hasholzner U; Fabricius PG; Schambeck C; Weinzierl M; Poley S; Samtleben W; Hofmann K; Meier W
    Int J Biol Markers; 1994; 9(2):82-8. PubMed ID: 7523546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
    Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
    Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.